Department of Otolaryngology-Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Department of Oral and Maxillofacial Surgery, Asahi University Murakami Memorial Hospital, Gifu, Japan.
Anticancer Res. 2014 Jun;34(6):2907-11.
Acquired chemoresistance to 5-fluorouracil (5-FU) remains one of the obstacles for the success of 5-FU-based cancer chemotherapy, and some molecular mechanisms of acquired 5-FU resistance are still unknown. The main action of 5-FU is the suppression of DNA replication by inhibiting Thymidylate Synthase (TS).
We analyzed 5-FU resistance mechanisms using the head and neck squamous cell carcinoma cell lines, UM-SCC-23, and two different resistant cell lines, UM-SCC-23/WR and UM-SCC-23/MR, which were procured from UM-SCC-23 cells. To acquire resistance, the two cells underwent repeated treatment of 5-FU with different durations and frequency. We determined differences in the cell-cycle distribution and the expression of TS proteins in the three cell lines. Moreover, cell-cycle distribution in cells which acquired resistance after 5-FU treatment, was compared to that of parental cells, using flow cytometric analysis.
There was a remarkable increase in TS protein expression levels in UM-SCC-23/WR following 5-FU treatment. S-phase cells of UM-SCC-23 and UM-SCC-23/WR cells were immediately increased after treatment with 5-FU, whereas UM-SCC-23/MR were accumulated to the S-phase slightly later.
The cell-cycle perturbation or elevation of TS protein expression may be involved in acquired 5-FU resistance and identifies 5-FU resistance mechanisms in the two different 5-FU treatment regimens.
对 5-氟尿嘧啶(5-FU)的获得性化学耐药性仍然是基于 5-FU 的癌症化疗成功的障碍之一,并且一些获得性 5-FU 耐药的分子机制尚不清楚。5-FU 的主要作用是通过抑制胸苷酸合成酶(TS)来抑制 DNA 复制。
我们使用头颈部鳞状细胞癌细胞系 UM-SCC-23 以及两种不同的耐药细胞系 UM-SCC-23/WR 和 UM-SCC-23/MR 来分析 5-FU 耐药机制,这些细胞系是从 UM-SCC-23 细胞中获得的。为了获得耐药性,两种细胞经历了不同持续时间和频率的 5-FU 重复治疗。我们确定了三种细胞系中细胞周期分布和 TS 蛋白表达的差异。此外,使用流式细胞术分析比较了经 5-FU 处理后获得耐药性的细胞与亲本细胞的细胞周期分布。
在经过 5-FU 处理后,UM-SCC-23/WR 中的 TS 蛋白表达水平显著增加。UM-SCC-23 和 UM-SCC-23/WR 细胞的 S 期细胞在 5-FU 处理后立即增加,而 UM-SCC-23/MR 细胞则稍晚积累到 S 期。
细胞周期紊乱或 TS 蛋白表达水平升高可能参与了获得性 5-FU 耐药,并确定了两种不同 5-FU 治疗方案中的 5-FU 耐药机制。